Life-Threatening Abnormal Behavior Incidence in 10-19 Year Old Patients Administered Neuraminidase Inhibitors

Much discussion has surrounded the association between the administration of neuraminidase inhibitors (NI) and severe abnormal behaviors, including sudden running away and jumping from a high place, which can be life-threatening if no one intervenes. Using data on the number of abnormal behaviors an...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-07, Vol.10 (7), p.e0129712-e0129712
Main Authors: Nakamura, Yuuki, Sugawara, Tamie, Ohkusa, Yasushi, Taniguchi, Kiyosu, Miyazaki, Chiaki, Momoi, Mariko, Okabe, Nobuhiko
Format: Article
Language:English
Subjects:
Adolescent
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Behavior
Child
Councils
Dangerous Behavior
Delirium
Enzyme Inhibitors - adverse effects
Enzyme Inhibitors - therapeutic use
Exo-a-sialidase
Family medical history
Female
Food
Health insurance
Humans
Incidence
Infectious diseases
Influenza
Influenza, Human - complications
Influenza, Human - drug therapy
Influenza, Human - epidemiology
Inhibitors
Inserts
Japan - epidemiology
Male
Medical personnel
Mental Disorders - epidemiology
Mental Disorders - etiology
Metabolic syndrome
Neuraminidase - antagonists & inhibitors
Patients
Pharmaceuticals
Physicians
Prescription drugs
Product safety
Reference materials
Risk taking
Sanitation
Seasons
Studies
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Much discussion has surrounded the association between the administration of neuraminidase inhibitors (NI) and severe abnormal behaviors, including sudden running away and jumping from a high place, which can be life-threatening if no one intervenes. Using data on the number of abnormal behaviors and patients who had been prescribed NI in Japan, we calculated the incidence rate of severe abnormal behaviors among influenza patients who had been prescribed NI. Then, we evaluated the relative risk between the four types of NI on severe abnormal behavior. We found no significant difference in the incidence rates of abnormal behavior by the type of NI. Results implicate that the current policy of package inserts, which warn physicians that patients who were administered ANY type of NI might exhibit abnormal behavior, seems to be appropriate.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0129712